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macaques (Macaca fascicularis) which resulted in disease similar in presentation to hemorrhagic smallpox in
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including lymph nodes, thymus, spleen, bone marrow, and lungs. This unique model of hemorrhagic
orthopoxvirus infection provides an accessible means to further study orthopoxvirus pathogenesis and to
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The threat of intentional release of variola virus (VARV),
the causative agent of smallpox, continues to be a chief biodefense
concern as the proportion of the world population without prior
vaccination expands. The most common form of disease, classical
smallpox,was associatedwith a case fatality rate of 30% in unvaccinated
individuals, thereby constituting a grave concern for public health if
VARV is re-introduced. Zoonotic orthopoxviruses including cowpox
(CPXV) and particularly monkeypox virus (MPXV) currently cause
sporadic disease in humans (Parker et al., 2007; Vorou et al., 2008), with
case-fatality rates fromMPXV infections reaching as high as 10% (Jezek
et al., 1983, 1988; Likos et al., 2005). (Rimoin et al., 2010) recently
described a considerable increase in the incidence of MPXV in the
Democratic Republic of Congo. Based on the above considerations,
investigations into orthopoxviral pathogenesis and the identiﬁcation of
countermeasures have accelerated over the past decade (Chapman
et al., 2010; Earl et al., 2008; Huggins et al., 2009; Jahrling et al., 2004;
Sbrana et al., 2007).
The development of animal models that accurately reﬂect human
disease is critical to our understanding of the pathogenesis of VARV
infection and evaluation of countermeasures against the orthopox-viruses. Because of the successful eradication of smallpox and the
sporadic and geographically isolated nature of MPXV outbreaks, the
only option for licensing new drugs and vaccines for smallpox and
other orthopoxvirus diseases is extrapolation of data derived from
accurate, validated animal models (Anon., 2009; Geisbert and
Jahrling, 2004; Kramski et al., 2010; Sullivan et al., 2000). The “Animal
Rule” requires that a countermeasure be evaluated in at least 2 animal
models in which the route and dose of virus administration, time to
onset of disease, and time course/progression of disease optimally
mimic the pathophysiology of the human disease. While VARV and
MPXV nonhuman primate (NHP) models in cynomolgus and rhesus
macaques have been used successfully for evaluation of vaccines and
antiviral therapies (Earl et al., 2004, 2008; Edghill-Smith et al.,
2005a,b; Hooper et al., 2004; Jahrling et al., 2005; Sbrana et al., 2007;
Stittelaar et al., 2001, 2005, 2006), biosafety and security restrictions
on the use of both viruses limit their widespread use by the research
community. MPXV experimentation requires Centers for Disease
Control and Prevention (CDC) Select Agent registration and biosafety
laboratory (BSL)-3 containment. VARV research is highly restricted to
BSL-4 containment at the CDC in the United States or the State
Research Center of Virology and Biotechnology (Vector) in Russia and
requires World Health Organization approval. In addition to the need
for animal models that accurately reﬂect all manifestations of
smallpox, the future of VARV research is uncertain due to increasing
international political interest in eradication of known VARV stocks
(Lane and Poland, 2011; McFadden, 2010; Tucker, 2011). Therefore,
Table 1
Survival and lesion count of NHPs infected with cowpox virus.
Dose
(PFU)
Group
size
Survival
(%)
Mean day of
endpoint (range)
Peak lesion
count (range)
Mean day of lesion
onset (range)
5×105 4 0 9.0 (7–12) 103 (0–306) 9.0 (8–10)
5×106 4 0 8.0 (7–9) 6 (0–13) 8.0 (n/a)
5×107 6 0 6.7 (5–11) 76 (0–184) 4.2 (3–8)
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available to the broader research community would serve as a distinct
advantage to accelerate research and complement or if necessary,
potentially replace the VARV NHP model for efﬁcacy studies of
countermeasures.
In contrast to VARV or MPXV, CPXV can be studied under BSL-2
laboratory conditions and does not require Select Agent registration.
CPXV is known to be highly virulent in mice, and intraperitoneal,
intranasal, and aerosol routes of administration have been used to
study the efﬁcacy of antivirals (Bray and Buller, 2004; Smee et al.,
2008). Recently, outbreaks of CPXV disease in NHPs housed in
European zoos have been reported, and lethal disease was reported in
common marmosets (Martina et al., 2006; Matz-Rensing et al., 2006).
Experimental studies using the isolated CPXV strain determined that
the lethal dose50 via intranasal inoculation in marmosets was b103
PFU and that the strain produced some typical signs of poxviral
disease (Kramski et al., 2010). While establishing the marmoset
infection model was signiﬁcant, previous orthopoxvirus research has
predominantly used macaque species (Chen et al., 2005; Earl et al.,
2008; Edghill-Smith et al., 2005a; Hooper et al., 2004; Huggins et al.,
2009; Jahrling et al., 2004; Stittelaar et al., 2001) and critical reagents
are readily available for macaques. To compare CPXV-induced disease
to the established macaque models of VARV and MPXV, more
extensive analysis of CPXV in macaques is required.
Here we demonstrate that intravenous (IV) inoculation of CPXV
Brighton Red strain in cynomolgus macaques (Macaca fascicularis)
resulted in severe hemorrhagic disease with rapid mortality using an
inoculum as low as 5×105 PFU. Clinical, hematological, and histopath-
ological analysis provided evidence for hemorrhagic disease with
similarities to both the NHP model of VARV infection (Jahrling et al.,
2004) and human hemorrhagic smallpox.While hemorrhagic smallpox
was a rare manifestation of disease (b3% of cases), it was rapid, severe,
and nearly uniformly fatal (Dixon, 1962; Downie et al., 1969; Fenner,
1988a). These ﬁndings represent the ﬁrst step in developing CPXV
infection inmacaques as amodel to complement existing orthopoxvirus
models.
Results
CPXV infection results in a rapid and lethal disease with hemorrhagic
manifestations
Fourteen cynomolgus macaques were inoculated intravenously
with 10-fold dilutions of CPXV in two independent experiments;
experiment one comprised one dosage group of 5×107 PFU (n=3)
and experiment two comprised three dosage groups of 5×107 PFU
(n=3), 5×106 (n=4), and 5×105 (n=4). Except where noted, all 6
NHPs receiving 5×107 PFU CPXV are included for analysis. Infection
resulted in a fulminant disease with hemorrhagic manifestations that
was dose-independent. Clinical signs of disease included depression,
lethargy, inappetence, ecchymoses, petechia, weakness, hematuria,
and proteinura. Less common clinical signs were diarrhea, melena,
and weight loss. Typical poxviral exanthema and enanthema
developed and are described below (Table 1). NHPs becamemoribund
and reached clinical endpoint criteria for euthanasia as described in
the Materials and methods between days ﬁve and twelve post-
inoculation.
Gross and histopathological ﬁndings indicate severe hemorrhagic disease
Comprehensive postmortem examinations were performed when
NHPsmet endpoint criteria ondays 5, 5, 6, 6, 7, and11 for the5×107 PFU
group; days 7, 8, 8, and 9 for the 5×106 PFUgroup; and days 7, 7, 10, and
12 for the 5×105 PFU group (Table 1). The classic hallmarks of
orthopoxvirus infection, exanthemaandenanthema(Jezek et al., 1987b;
Martin, 2002), were less numerous in NHPs infected with CPXVcompared to other orthopoxvirus NHP models (Jahrling et al., 2004;
Johnson et al., 2011). Lesions developed in 9 of 14NHPs, but peak lesion
counts (Table 1)were below levels typically observed inMPXV or VARV
infection (Fenner, 1988a; Huggins et al., 2009; Johnson et al., 2011;
Ricketts, 1910; Stittelaar et al., 2005, 2006). Cutaneous and mucosal
lesions developed on the face, extremities, thorax, abdomen, oral
mucosa, pharynx, and anogenital region, and often appeared hemor-
rhagic (Fig. 1A). In addition, cutaneous erythema and ecchymoses,
independent of vesicular lesions, were common (Fig. 1B). Other gross
ﬁndings included lymph node hemorrhage and edema (Fig. 1C),
multifocal petechial hemorrhages on the mucosal surface of the
gastrointestinal tract (Fig. 1D), and multifocal petechial hemorrhages
on heart, lungs, kidneys, urinary bladder, and brain (data not shown).
Histopathological evaluation conﬁrmed severe hemorrhagic
involvement of multiple components of the skin and mucous mem-
branes, with no correlation between inoculation dose and lesion
severity or distribution. Skin and mucous membrane changes included
typical intraepidermal vesicles, swollen keratinocytes (ballooning
degeneration) with intracytoplasmic inclusion bodies, ulceration, and
dermal/submucosal hemorrhage and edema. Similar to other chordo-
poxviruses, the inﬂammatory cellular inﬁltrate ranged from neutro-
philic inﬁltrate within the stratum corneum of the epidermis
(subcorneal pustules) to a mononuclear inﬁltrate within the vesicular
lesions of the epidermis. Secondary lymphoid organs including spleen,
lymph node, and tonsil were often severely affected, and changes
included necrotizing tonsillitis, lymphoid necrosis and depletion,
sinusoidal edema, hemorrhage, and ﬁbrin deposition occurring in
14/14 NHPs and intralesional bacteria occurring in 6/14 NHPs (Figs. 2A
and B). Immunohistochemical (IHC) staining frequently revealed viral
antigen in lymphnodes and spleen (Figs. 3A andB). In3/14NHPs, severe
diffuse hematopoietic necrosis with hemorrhage, congestion, and
intralesional bacteria was found (Fig. 2C). As in the lymphoid organs,
necrotic areas of bone marrow were positive for poxviral antigen as
assessed immunohistochemically (Fig. 3C). Examination of the heart
revealed multifocal lymphohistiocytic myocarditis in all NHPs with
myoﬁber degeneration necrosis, vascular congestion and hemorrhage
(Fig. 2D); immunohistochemically, viral antigen was present in
mononuclear cells within the interstitium (Fig. 3D).
Other ﬁndings included interstitial pneumonia (14/14 NHPs),
interstitial nephritis (14/14 NHPs), and hepatitis (14/14 NHPs). Viral
antigen stainingwas sporadically found inmononuclear cellswithin the
renal interstitium and glomeruli. 3/14 NHPs were found to be positive
for bacteria in the blood by culturing blood samples on blood and
chocolate agar at necropsy, although no further testing was performed
to deﬁnitively identify the bacteria. In 6/14 NHPs (including the 3
positive by culturing blood), intralesional colonies of Gram positive or
Gram negative bacteria were found in 5 or more different organs
indicating concurrent development of a secondary bacterial infection.Hematological analyses indicate signs of hemorrhage and coagulopathy
Red blood cell count, hematocrit, and hemoglobin concentrations
were monitored periodically pre- and post-inoculation (Figs. 4A–C).
All 3 parameters decreased dramatically during the course of infection,
consistent with the observed hemorrhagic signs. The development of
anemiawas not dose-dependent and appeared consistently byday 5 or
at the time of moribund endpoint. Concurrent with the development
Fig. 1. Gross pathology of CPXV-infected NHPs indicates a systemic hemorrhagic disease. A. Hemorrhagic skin lesion. B. Ecchymoses on skin. C. Hemorrhage and edema of lymph
nodes. D. Petechiae on gastrointestinal tract mucosa (stomach).
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intravascular coagulation (DIC). Speciﬁcally, thrombocytopenia,
elevated PT, and increased FDP and D-dimer concentrations in serum
were detected (Figs. 4D–H). Thrombocytopenia was the only evalu-
ated hemostatic parameter that may be dose-dependent (Fig. 4D). PT
increased in 9 of 11 NHPs and typically peaked at endpoint (Fig. 4F).
Further support for DIC included elevations in the concentration of
FDPs (Fig. 4G) and D-dimers (Fig. 4H) that were detected in the serum
of 13 of 14 NHPs. Mean peak D-dimer concentrations increased
approximately 1000-fold from baseline across the dosage groups.
Interestingly, aPTT decreased in 7/11 NHPs, remained within normal
range in 3 NHPs, and increased in a single NHP inoculatedwith 5×105
PFU that survived to day 12 (Fig. 4E).
PBMC analysis indicates expansion of adaptive immune cells and depletion
of innate immune cells
Concentrations of CD14+ (monocytes), CD16+ (NK cells), CD4+
(helper T-cell), CD8+ (killer T-cell), and CD20+ (immature B-cell) cell
populationswere assayed by TruCountmethodology as described in the
Materials and methods at periodic blood draws and at moribund
endpoint. Analysis of the PBMC proﬁles revealed two patterns thatwere
consistently observed across dosage groups (Fig. 5). First, circulating
CD14+ and CD16+ cells were largely depleted as NHPs met moribund
endpoint criteria with the exception of a single NHP in the 5×106 PFU
group which had an elevated level of CD14+ cells. Preceding this
decline in innate immune cell populations, two-fold or greater increases
in CD14+or CD16+cell concentrationswere observed in 9/11and5/11
NHPs, respectively, indicating an initial pro-inﬂammatory response.
Second, further support for the pro-inﬂammatory response wasprovided by the consistent elevation of adaptive immune cells.
Speciﬁcally, 10/11 NHPs had two-fold or greater rises in circulating
CD4+, CD8+, and CD20+ cell populations at late stages of the disease
course. In NHPs that survived past day 8 in the 2 lower dosage groups,
relative declines in CD4+, CD8+, and CD20+ cell populations to pre-
infection concentrations were observed. Using a ﬂow cytometric
neutralizing antibody assay, we were unable to detect any neutralizing
antibody activity in the CPXV-infected NHPs (data not shown). Speciﬁc
T cell responses were not assayed.
Cytokine/chemokine response to hemorrhagic CPXV infection
The pro-inﬂammatory cytokines/chemokines monocyte chemoat-
tractant protein-1 (MCP-1 or CCL2), interleukin-6 (IL-6), IL-8, and
interferon-γ (IFN-γ) were previously reported to be elevated in VARV-
infectedNHPs that developedhemorrhagic disease andwere therefore a
focus in this study (Fig. 6) (Jahrling et al., 2004). MCP-1 and IL-8
concentrations rose in the majority of NHPs after days 3–4 post-
inoculation in CPXV-infected NHPs in a dose-independent manner and
typically did not start to increase until after days three to four. However,
two NHPs in the 5×107 PFU group reached peak concentrations of
MCP-1 at day four post-infection which was maintained in 1 NHP until
endpoint criteriaweremet. In contrast, elevations in IL-6 concentrations
were suggestive of dose-dependence. IFN-γ concentrations followed a
different pattern of activation, with peak values reached in the 5×106
PFU and 5×107 PFUgroups primarily between days 3 and 4 followed by
a decrease in concentrations prior to moribund endpoint. Elevations of
IFN-γ concentrations in the 5×105 PFU group were less pronounced.
Peak concentrations for MCP-1 (14/14 NHPs), IL-6 (10/14 NHPs), and
IL-8 (13/14 NHPs) coincided with endpoint.
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(IL-1ra), IL-18, RANTES, soluble CD40 ligand (sCD40L), granulocyte
colony stimulating factor (G-CSF), and vascular endothelial growth
factor (VEGF) were also elevated after CPXV infection (Table 2). IL-1ra,
IL-18, andVEGFhad thehighest andmost consistent elevationsbetween
the groups and peak concentrations coincided withmoribund endpoint
suggesting their importance in disease outcome. No signiﬁcant changes
were identiﬁed for levels of granulocytemacrophage colony stimulating
factor (GM-CSF), macrophage inﬂammatory protein-1 α and β
(MIP-1α, MIP-1β), IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-15,
IL-17, transforming growth factor-α (TGF-α), or tumor necrosis
factor-α (TNF-α).
CPXV replication was observed in multiple organ systems
Viral load in the blood as measured by qPCR (viremia) and oral and
nasal swabs indicated CPXV replication that was largely dose-
independent (Table 3). Mean peak viremia ranged from 8.4 to 9.1
log10 gene copies/mL across the dosage groups and coincided with
moribund endpoint for 10/13 NHPs evaluated (data not shown). Virus
shed fromoral and nasalmucosawas detected as early as day three/four
post-infection in all NHPs and similarly peaked at the time of endpoint.
At the time of necropsy, tissue homogenates were isolated from 41
tissues and assayed for viral load by plaque assay. As expected, CPXV
widely disseminated and commonly reached virus titers of greater than
6.0 log10 PFU/g of tissue or greater (Fig. 7). Lymphoid tissues, including
spleen, lymph node, thymus, and tonsil, and bonemarrowwere typical
sites of high CPXV replication, consistent with previous orthopoxvirus
studies (Johnson et al., 2011; Jordan et al., 2009). Additional sites of high
viral loads included the nares, lungs, liver, kidneys and adrenal glands.
Discussion
The present study indicates that infection of cynomolgus macaques
with CPXV Brighton Red may be a suitable model for hemorrhagicFig. 2. Hematoxylin and eosin staining of lymph node, spleen, bone marrow, and the heart co
and intralesional bacteria (arrow). (B) Spleen (20×): diffuse necrotizing splenitis with hemo
with necrosis, intracellular bacteria (arrow). Inset: viral intracytoplasmic inclusion. (D) Hea
non-suppurative myocarditis. Inset: the black arrow indicates myocardial necrosis, white asmallpox. Hemorrhagic smallpox was the most severe clinical presen-
tation of VARV infection in humans, resulting in almost 100% lethality.
To date, the onlymacaquemodel of hemorrhagic orthopoxvirus disease
requires IV inoculation of 1×109 PFU of VARV into cynomolgus
macaques (Jahrling et al., 2004). However, variola research is highly
restricted, and the high virus titer (10,000-fold higher than the lowest
lethal dose reported here) required to induce uniformly lethal disease
indicates the need for additional models of orthopoxvirus infection.
Development of improved NHP orthopoxvirus models must rely on
expanding what has been learned from IV inoculationmodels, because,
although IV inoculation does not reproduce natural transmission and
essentially skips the prodromal phase of disease, it repeatedly results in
fulminant disease characteristic of severe classical pox-like disease and
has been used to successfully evaluate anti-orthopoxvirus therapeutics
and vaccines (Earl et al., 2004, 2007, 2008; Edghill-Smith et al., 2005a,b;
Huggins et al., 2009; Stittelaar et al., 2001, 2005, 2006). Improvements in
MPXV disease modeling have come from studies of airway and
respiratory exposure routes including aerosol, intrabronchial, and
intratracheal, but these methods may be hampered by exaggerated
respiratory disease, decreased lesional disease, and variable disease
presentation andoutcome(Goff et al., 2011; Johnsonet al., 2011; Zaucha
et al., 2001). Therefore, while intravenous inoculation is imperfect, it is a
viablemethod to test the efﬁcacy of countermeasures under an extreme
form of viral challenge. There is no current indication that a
countermeasure that protects against intravenous challenge and its
associated rapid, fulminant disease would fail against respiratory
challenge which may result in slower disease progression. However,
further development of respiratory models is clearly warranted.
Investigation of CPXV as amodel of human smallpox is supported by
analysis of the data reviewed by (Seet et al., 2003) that indicates that
VARV and CPXV share 19 immunomodulatory genes based on function.
CPXV encodes 3 additional proteins when compared to VARV, all
targeting the TNF-α pathway (CrmC, CrmE, and CrmD). By comparison
MPXV shares 14 immunomodulatory genes with VARV with 2 proteins
not shared with VARV, CrmE (a TNF-α pathway inhibitor) and CD-46, allected at necropsy from CPXV-infected NHPs. (A) Lymph node (20×): necrosis, edema
rrhage, ﬁbrin and intralesional bacteria (arrow). (C) Bone marrow (40×): hypocellular
rt (20×): lymphohistiocytic myocarditis with myoﬁber degeneration, hemorrhage, and
rrow indicates lymphohistiocytic inﬁltration of the myocardium.
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suggests that, depending uponmethodology, CPXVmay bemore closely
related to VARV thanMPXV (Gubser et al., 2004; Lefkowitz et al., 2005;
Xing et al., 2006). For example, (Gubser et al., 2004) demonstrated that
by the maximum-likelihood method using nucleotide sequences that
CPXV-Brighton Red is more closely related to VARV than MPXV. In
contrast Xing et al. demonstrated by gene sequence homology based on
most parsimonious trees using amino acid sequence of 49 shared genes
thatMPXVandCPXVweremore closely related to eachother thaneither
was to VARV. Analysis of the same 49 shared genes by the neighbor-
joining tree method indicated that MPXV was more closely related to
VARV thanwasCPXV(Xinget al., 2006).While high sequencehomology
of a surrogate orthopoxvirus is a chief consideration in model
development, it should be noted that the similarity of disease
presentation in the animal model may be equally as important in the
demonstration of countermeasure efﬁcacy.
Clinical presentation of hemorrhagic CPXV disease after IV inocula-
tion of CPXV shares several features with hemorrhagic smallpox in
humans. Clinical signs such as increased PT, increased D-dimers, FDP,
and thrombocytopenia indicating DIC were similar to the coagulation
disorders reported in human hemorrhagic smallpox (Haviland, 1952;
McKenzie et al., 1965; Roberts et al., 1965). Although increased aPTT is
often associated with DIC, decreases in aPTT can occur in DIC as part of
the initial acute phase reaction (Favaloro, 2010). Gross observations
such as erythematous, petechial, and hemorrhagic lesions involving the
face, oronasal cavities, thoraco-abdominal and anogenital regions, and
upper torso of NHPs in this study resemble the erythema, petechiae, and
hemorrhage on the mouth, oral cavity, arms, and trunk observed in
patients with hemorrhagic smallpox (Bras, 1952; Haviland, 1952;
McKenzie et al., 1965; Rao, 1964; Roberts et al., 1965). Histopathologic
similarities in examined tissues included: hemorrhage, lymphoid
depletion, hepatocyte necrosis, and hypocellularity of the bonemarrow
observed in the present study (Bras, 1952; Councilman et al., 1904a;
Martin, 2002). Bacteremia, which likely contributed to disease, was
commonly observed in both human hemorrhagic smallpox and CPXV
infection described here (Councilman et al., 1904b; Kempton andFig. 3. Immunohistochemistry of lymph node, spleen, bone marrow and heart collected a
follicular and paracortical poxvirus antigen staining. (B) Spleen (20×): diffuse poxvirus antig
hypocellularity with immunopositive myeloid cells within areas of necrosis. (D) Heart (20×Parsons, 1920; Ricketts, 1910). Death or moribund endpoint occurred
within 5–12 days post exposure in both conditions. We note that in
CPXV-infected marmosets, (Kramski et al., 2010) observed focal
hemorrhages near lesion sites as well as petechiation of the larynx
and parts of the thorax, but there was no indication of systemic
hemorrhagic disease as described here.
Differences were also observed between human hemorrhagic
smallpox and experimental CPXV-induced disease. Fewer cutaneous
lesions were observed during CPXV-induced disease than what was
observed in patients with hemorrhagic smallpox (Fenner, 1988a;
Martin, 2002) and VARV-inoculated NHPs (Jahrling et al., 2004).
Interestingly, human cases of CPXV are often characterized by a single
or few lesions suggesting that fewer cutaneous lesions are a common
feature in humans (Baxby et al., 1994) and NHPs. Cardiac changes in
human hemorrhagic smallpox included multifocal myocardial and
subendocardial hemorrhage (Bras, 1952; Lillie, 1930). Lymphohistiocy-
tic myocarditis, as was seen in this study, was also reported in human
smallpox but this lesion was not classiﬁed by disease type (Bras, 1952;
Councilman et al., 1904a; Fenner, 1988b). Fever was also only observed
in 2/14 NHPs in this study while fever was often more severe in
hemorrhagic smallpox when compared to classical smallpox indicating
an apparent difference between this model and human disease
(Councilman et al., 1904b; Ricketts, 1910). Although temperature
increases were observed in NHPs it is unknown if the observed increase
is affected by anesthesia, and it is also possible that a short lived fever
would not beobserveddue to the physical examschedule. Alternatively,
it is possible that cowpoxmodulates IL-1 receptor signaling resulting in
lack of fever response by the NHPs. Telemetry may be implemented as
part of future studies to gathermeaningful data to determine the role of
fever in this CPXV model.
Direct comparison between cytokine concentrations in human
hemorrhagic smallpox andCPXVcannot beperformedbecause cytokine
data from human cases has not been reported. IL-6, IL-8, and MCP-1
have been implicated in responses that may promote coagulation
disorders in other diseases (Charo and Taubman, 2004; Huerta-Zepeda
et al., 2008; Johnson et al., 1998; Levi and van der Poll, 2010) and hight necropsy using cross-reactive anti-vaccinia virus staining. (A) Lymph node (20×):
en within areas of necrosis and capsular mesothelium (arrow). (C) Bone marrow (40×):
): immunopositive mononuclear cells within the interstitium.
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factor expression (Charo and Taubman, 2004; Levi and van der Poll,
2010) which may help initiate the extrinsic coagulation cascade. Our
cytokine and chemokine analysis indicated a pro-inﬂammatory re-
sponsewith elevations in MCP-1, IL-18, and IFNγ. MCP-1, IL-6 and IFNγ
were of particular interest because they were elevated in NHPs
inoculated with VARV Harper (Jahrling et al., 2004). However, during
CPXV infection IL-8 and IL-6 did not increase in all NHPs suggesting that
they may play a limited role in CPXV induced disease.
Comparison of cytokine concentrations in NHPs inoculated with
5×107 PFU IV MPXV (dose with highest lethality) to CPXV revealed
similar peak fold changes of 1.3, 1.6, and 1.9-fold for MCP-1, IL-6, and
IL-8, respectively. In contrast, during MPXV infection, IFNγ increases
400-fold and only 21-fold in CPXV inoculated NHPs across all 3 doses
reported here. IL-18 was not elevated in MPXV but was elevated on
average 460-fold across all 3 doses in CPXV inoculated NHPs. The data
suggests a complex interplay between cytokines and chemokines
involving concentrations relative to each other, timing of induction,
and combinations of cytokines that may partly determine disease
presentation and outcome. When compared to Ebola hemorrhagic
fever in humans, several similarities exist: IL-4 is not abundantly
expressed in either disease. However, RANTES, IL-6, and IL-8 demon-
strated approximately 6 fold (500 pg/mL peak average), 10 fold
(1000 pg/mL peak average), and 10 fold (500 pg/mL peak average)
increases in nonsurvivors when compared to survivors of SEBOV
infection. During Zaire Ebola Virus (ZEBOV) infection IL-6, IL-8, and
MCP-1 demonstrated approximately 1.5 (100 pg/mL peak average)
fold, 15 fold (1000 pg/mL peak average), and 7.5 fold (750 pg/mL peak
average) increases in concentrations in ZEBOV induced disease.
Differences include a 10 fold increase in TNFα expression in Ebola-
infected humans and no signiﬁcant upregulation of IFNγ (Hutchinson
and Rollin, 2007; Wauquier et al., 2010).
The lymphoid pathogenesis and decline in innate immune cells
observed during CPXV infection may provide a unique opportunity to
identify the impact of the mononuclear phagocytic and lymphoid
systems in orthopoxvirus disease progression. The observed decline in
the innate immune cells present in the PBMC population may be the
result of either the loss of progenitor hematopoietic cells or direct viralCBA HCTRBC
GFE aPTT PT
Fig. 4. Hematology supports a consumptive coagulopathy. (A) Red blood cell count, (B) hem
(F) prothrombin time (PT), (G) ﬁbrin degradation products (FDP), and (H) D-dimer measure
(n=4), red line represents 5×106 PFU group (n=4), and blue line represents 5×107 PFU
represent standard deviation.cytopathic effects within the monocyte–macrophage system and
lymphoid system, either of which would exacerbate disease. Bone
marrow hypocellularity could represent the loss of precursor pluripo-
tent cells due to direct lytic infection by CPXV or an indirect effect of
infection, but the cause of such changes is unknown. In animals that
survived past day 8, CD14+, CD16+, CD4+, CD8+, and CD20+ cell
populations sharply declined prior tomoribund endpoint. Disruption of
the bone marrow and lymphoid tissue likely plays a key role in disease
outcome because these PBMC cell populations are ultimately replen-
ished from the bone marrow and undergo maturation in lymphoid
tissue. Further investigations with this model may help delineate the
role of the individual PBMC populations in disease progression.
Immunosuppression presumably played a role in the development
of secondary bacterial infections observed in six NHPs. The contribution
of these secondary infections to disease outcome cannot be discerned in
this study, but bacterial infection may have exacerbated lymphoid
necrosis and depletion, bone marrow disruption, skin and GI tract
lesions. CPXV-induced damage to the GI mucosa could increase
intestinal mucosal permeability leading to bacteria accessing the
circulatory system. Similarly, loss of integrity of skin and oral mucosa
also invites invasion of bacteria. Gram positive and gram negative
bacteria were observed in the blood vessels and tissues, but no further
identiﬁcationwas attempted. Secondary bacterial infections, notably by
hemolytic streptococci in human smallpox (Kempton and Parsons,
1920), have been reported as complicating factors in humans with
monkeypox and smallpox (Bras, 1952; Dixon, 1962; Jezek et al., 1987a;
Martin, 2002) and experimental MPXV-induced disease (Johnson et al.,
2011; Saijo et al., 2009; Zaucha et al., 2001).
Of the types of smallpox, hemorrhagic smallpox was rare but the
most severe with the highest case fatality rate (Fenner, 1988a; Rao,
1964). This hemorrhagic CPXV model closely parallels human hemor-
rhagic smallpox and the VARV NHP model of hemorrhagic smallpox
indicating that further studies of CPXV pathogenesis are warranted. As
CPXV is a BSL-2 pathogen, this model could be used more widely to
develop countermeasures that could then be tested against VARV in
compliance with the FDA animal rule (Chapman et al., 2010; Lane and
Poland, 2011; McFadden, 2010). Furthermore, the uncertain future of
VARV research necessitates additional development of this CPXV andD PlateletsHGB 
HFDP D-Dimer 
atocrit, (C) hemoglobin, (D) platelets, (E) activated partial thromboplastin time (aPTT),
d at times of periodic blood draw and necropsy. Black line represents 5×105 PFU group
group (n=6) except for aPTT and PT where the 5×107 PFU group has an n of 3. Bars
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Studies to determine if inoculation of NHPs with a lower dose of CPXV
would result in more classical poxviral disease with lesser hemorrhagic
signs and increased lesion development are ongoing. Additionally,
exploration of other inoculation routes is warranted as this study and IV
inoculation represent the ﬁrst steps in investigation of CPXV in
macaques as an alternate model of orthopoxvirus disease. Future
studies will also aim to identify viral and host factors which lead to
hemorrhagic poxviral disease and lethality. The cause of death from
human hemorrhagic smallpoxwas often referred to as toxemia ormore
recently a cytokine storm (Councilman et al., 1904a; Fenner, 1988b;
Jahrling et al., 2004; Martin, 2002; Ricketts, 1910). However, toxemia
was poorly deﬁned due to technological limitations and the exact cause
of death remains unknown. Themechanism bywhich VARVmanifested
as a hemorrhagic disease rather than classical smallpox is alsounknown,
but likely involves a combination of multi-organ system failure,
coagulopathy, dysregulation of the cytokine response, immune system
compromise, and opportunistic bacterial infections. Further develop-
ment of this model may identify viral and host factors leading to
hemorrhagic disease and aid therapeutic development.Materials and methods
Virus and cells
CPXV Brighton Red strain was propagated in Vero E6 cells at a
multiplicity of infection (MOI) of 0.1 for 7 days. Virus was then pelleted
over 36% sucrose at 25,000 rpm in a SW32ti rotor for 80 min at 4 °C. The
virus was kindly provided by Dr. GrantMcFadden, University of Florida.
Vero E6 cells were maintained in Dulbecco's modiﬁed Eagle's medium
(DMEM) (HyClone, Logan, UT) supplemented with 10% fetal bovine
serum (FBS) (HyClone, Logan, UT) and 1% penicillin/streptomycin at
37 °C with 5% CO2. BSC-1 cells were maintained in minimum essential
medium (MEM) supplemented with 10% FBS and 1% penicillin and
streptomycin at 37 °Cwith 5%CO2. Inoculawere prepared by disruption
of Vero E6 cells in an Ultrasonic Processor VCX-750 (Sonics and
Materials, Newtown CT) for 120 s at 40% power on ice followed by
centrifugation at 500 g for 10 min at 4 °C.CD14+ CD16+ CDA
B
C
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methods. Lines represent individual NHPs. (A) 5×105 PFU group (n=4), (B) 5×106 PFU gChallenge and monitoring of NHPs
Prior to enrollment, cynomolgus macaques (M. fascicularis), were
screened for simian retrovirus (SRV), simian T-lymphotrophic virus
(STLV), MPXV, vaccinia virus (VACV), and CPXV by quantitative
polymerase chain reaction (qPCR). Selected NHPs ranged in weight
from 2.7 to 4.2 kg. NHPs were also screened for detectable neutralizing
antibody activity against VACV. All animalprocedureswere approvedby
theNational Institute of Allergy and InfectiousDiseasesAnimal Care and
Use Committee and adhered to National Institutes of Health (NIH)
policies including those set forth in the Guide for the Care and Use of
Laboratory Animals.
For IV inoculation, NHPs were anesthetized with Telazol® (combi-
nation of tiletamine and zolazepam), and 1 mL of CPXV virus inoculum
was injected into the saphenous vein with a 21-gauge needle. Two
independent experiments were performed. In the pilot experiment, 3
NHPs were inoculated with 5×107 PFU and physical exams, including
temperature, body weight, and lesion counts, were performed.
Peripheral blood and oral and nasal swabs were collected on days 0, 4,
8, 10, and 12 post-inoculation. In the second experiment, 3 groups of
NHPswere inoculatedwith serial 10-fold dilutions of CPXV; 5×107 PFU
(n=3), 5×106 PFU (n=4), and 5×105 PFU (n=4). Physical exams
were performed and samples were collected in the samemanner as the
ﬁrst experiment on days −3, 3, 8, 10, and 12 post-inoculation. NHPs
weremonitored at least twice daily. A pre-established scale was used to
monitor clinical endpoint criteria that included scoring of (1) overall
clinical appearance, (2) respiratory abnormalities, (3) activity and
behavior, (4) responsiveness, and (5) core body temperatures.
Moribund clinical endpoint criteria were considered met and NHPs
euthanized when clinical signs including uncontrolled epistaxis,
melena, retrobulbar hemorrhage, respiratory distress, severe recum-
bency, non-responsiveness, and hypothermia were observed.
Hematology and serology
Complete blood counts including leukocyte differentials (CBC/diff)
were determined from blood samples collected in ethylenediaminete-
traacetic acid (EDTA)-coated blood tubes and analyzed using a Sysmex
XS1000i™ (Sysmex America, Mundelein, IL). To further analyze4+ CD8+ CD20+ 
y Day 
ns were assayed periodically by TruCount analysis as described in the Materials and
roup (n=4), and (C) 5×107 PFU group (n=3).
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109R.F. Johnson et al. / Virology 418 (2011) 102–112peripheral blood mononuclear cells (PBMCs), EDTA whole blood
samples were collected from NHPs and analyzed using TruCount™
tubes (BD Biosciences, San Jose, CA). A commercial antibody cocktail
containing markers for CD45, CD3, CD4, CD8, CD14, CD16, and CD20
(BD Biosciences, San Jose, CA) was brought up to a volume of 50 μL in
phosphate buffered saline (PBS) plus 2% fetal bovine serum (FBS) and
50 μL of cocktailwas transferred into a TruCount™ tube. Fiftymicroliters
of EDTAwhole bloodwas thenadded to the tube, gentlymixedbyvortex
and incubated for 20 min at room temperature. Samples were ﬁxed
using BD FACS Lysis Buffer (BD Biosciences San Jose, CA) and then
analyzed on the BD Fortessa Flow Cytometer. Data were analyzed using
FlowJo analysis software v8.6.3 (TreeStar Inc., Ashland OR). Cells were
ﬁrst gated on CD45, then CD3+ and CD3− populations were selected
against CD45. CD3+ populations were then gated against CD4 and CD8Table 2
Additional cytokines/chemokines with increased plasma concentrations.
Cytokine/
chemokine
Dose
(PFU)
Mean day of cytokine peak
(range)
Mean peak concentration
(range)
IL-1-ra 5×105 9 (7–12) 8878 (6163–11,596
5×106 6.75 (3–9) 4537 (41–9419)
5×107 6.67 (5–11) 9355 (7445–10,282
IL-18 5×105 9 (7–12) 715 (84–2458)
5×106 5.5 (3–9) 351 (60–683)
5×107 5.17 (3–11) 691 (30–2396)
RANTES 5×105 3.25 (2–7) 6072 (2567–14,760
5×106 2.5 (0–9) 4890 (1289–12,107
5×107 3.17 (0–11) 8325 (1786–17,517
VEGF 5×105 9 (7–12) 225 (64–279)
5×106 5.5 (3–9) 438 (43–1304)
5×107 6.67 (5–11) 763 (113–1544)
sCD40L 5×105 2.5 (0–7) 199 (55–289)
5×106 2.5 (0–7) 263 (83–462)
5×107 1.33 (0–5) 204 (84–530)
G-CSF 5×105 8.5 (7–10) 716 (175–1501)
5×106 6.75 (3–9) 2639 (49–6391)
5×107 6.67 (5–11) 3250 (344–7591)subpopulations. CD3− populations were gated against CD14, CD16 and
CD20 subpopulations.
For coagulation studies, samples were analyzed on a Thromboscreen
2000 (Paciﬁc Hemostasis and Fisher Scientiﬁc Diagnostics, Middletown,
VA) to determine activated partial thromboplastin time (aPTT) and
prothrombin time (PT). The concentration of D-dimers and ﬁbrin
degradation products (FDPs) was assayed from citrate-treated blood
samples using anenzyme-linked immunosorbent assay (ELISA) according
to the manufacturer's directions (Diagnostica Stago, Parsippany, NJ).
Quantiﬁcation of viremia by quantitative PCR
Viral load in whole blood was determined by quantitative PCR as
described previously (Kulesh et al., 2004). Brieﬂy, DNA was isolated(pg/mL) Mean fold change from day
zero
No. of NHPs with peak concentrations at
endpoint
) 6268 4/4
3645 3/3
) 4664 6/6
715 4/4
351 2/3
314 3/6
) 7 1/4
) 3 2/3
) 3 2/6
225 1/4
438 2/3
584 6/6
5 1/4
2 1/3
322 1/6
344 3/4
98 3/3
39 6/6
Table 3
Viral load in blood and in oral and nasal swabs.
Dose
(PFU)
Group
size
Viremia Oral swab Nasal swab
Mean peak (log10 gene copy/mL)
(range)
Mean day of peak
(range)
Mean peak (log10 PFU/mL)
(range)
Mean day of peak
(range)
Mean peak (log10 PFU/mL)
(range)
Mean day of peak
(range)
5×105 4 8.6
(8.5–8.7)
8.5
(7–12)
3.6
(2.6–4.0)
8.5
(7–12)
3.3
(2.0–3.7)
7.5
(7–8)
5×106 4 8.4
(5.0–8.8)
6.8
(3–9)
2.5
(2.0–3.0)
6
(3–8)
6.3
(2.0–6.7)
6.5
(3–8)
5×107 6 9.1
(8.2–9.8)
6.0
(4–10)
2.9
(2.5–3.3)
4.2
(4–7)
5.9
(3.2–6.4)
6.5
(4–11)
110 R.F. Johnson et al. / Virology 418 (2011) 102–112using Genﬁnd v2 according to manufacturer's directions (Agencourt,
Danvers MA) and isolated DNA was screened for the presence of CPXV
using primers speciﬁc for the HA gene (Soﬁ Ibrahim et al., 2003) and a
LightCycler apparatus (Roche, Basel Switzerland). The limit of detection
was 10 gene copies/mL.
Plaque assay
The concentration of infectious CPXV in oral and nasal swabs and
tissue samples was determined by plaque assay on BSC-1 cell mono-
layers. Swabswere placed in 1 mL of sterile 1× PBS, soaked for 30 s, and
stored at −80 °C. Swab suspensions were thawed and sonicated for
120 s on ice, serially diluted 10-fold, and then added to conﬂuent BSC-1
cells. Forty one tissues from each NHP were evaluated, and the tissues
with the highest and most consistent levels of virus replication are
described below. Tissue samples were excised during necropsy, ﬂash
frozen, and stored at−80 °C. Tissueswere homogenized (10%or 20%w/
v), and 10-fold serial dilutions were incubated on conﬂuent BSC-1 cells
with a 0.8% agarose:MEM2% FBS overlay. Following incubation, agarose
plugs were removed, the monolayers were stained with crystal violet
(0.1% crystal violet, 20% ethanol v/v), and plaques were enumerated.
Viral titers for the lymph nodes were the average of cervical, axillary,
bronchial, mesenteric, inguinal, and popliteal lymph node titers. Bone
marrow titers were the average of sternal, ilial, and femoral boneFig. 7. CPXV demonstrated wide tissue distribution. At necropsy, tissue samples were homog
titers are indicated for each tissue. Viral titers for the lymph nodes are the mean of cervical a
are the mean of sternal, ilial, and femoral bone marrow samples. Viral loads in lungs are th
cerebellum, cervical spinal cord, thoracic spinal cord, and lumbar spinal cord. Liver titers are
titers are the mean of both ovaries, kidneys and adrenal glands. Bars represent standard demarrow titers. Viral loads in lungs were the average titers of samples
from the 6 lobes for each NHP. CNS titers were the average of cerebrum,
cerebellum, cervical spinal cord, thoracic spinal cord, and lumbar spinal
cord titers. Liver titers were the average of left, right, medial, and caudal
liver lobe titers. Ovary, kidney and adrenal gland titerswere the average
of both ovaries, kidneys, and adrenal gland titers.Cytokine and chemokine analysis
The concentrations of 23 cytokines and chemokines in serum
samples were analyzed using the Millipore Non-Human Primate
Cytokine Panel Premixed 23-plex (Millipore Billerica MA). Plasma
samples were transferred to a 96-well plate and incubated with
antibody-coated beads directed against different cytokines or chemo-
kines. For the chemokine Regulated upon Activation, Normal T-cell
Expressed, and Secreted (RANTES) or CCL5, a 1:100 dilution was made
for each sample. Following incubation, the beads were washed,
incubatedwith anti-cytokine and chemokine antibodies, and incubated
with Streptavidin-R-phycoerythrin (SAV/RPE). Beads were assayed on
the Luminex 100/200 System (Bio-Rad, Hercules CA). Cytokines were
included for comparison when there was a twofold or greater change
above background detection of themanufacturer supplied standards for
any NHP within a group.enized and assayed for the presence of virus by plaque assay on BSC-1 cells. Mean virus
xillary, bronchial, mesenteric, inguinal, and popliteal lymph nodes. Bone marrow values
e mean titers of samples from the 6 lobes for each NHP. CNS is the mean of cerebrum,
the mean of left, right, medial, and caudal liver lobes. Ovary, kidney and adrenal gland
viation.
111R.F. Johnson et al. / Virology 418 (2011) 102–112Postmortem examination, histopathology and immunohistochemistry
All animals except one were necropsied on the day of death, and
gross lesions were recorded. One animal in the 5×106 PFU group was
not necropsied, and the reporting of this group is reﬂected as n=3
when appropriate. Blood samples and oral and nasal swabs were
collected. Tissues from allmajor organ systemswere collected and ﬁxed
in 10% neutral buffered formalin, embedded in parafﬁn, sectioned at
5 μm, and stained with hematoxylin and eosin (H&E) according to
established protocols. Separate tissue samples were collected and ﬂash
frozen for viral plaque assay as described above.
Immunohistochemistry (IHC)was performed on 5 μm thick sections
of formalin-ﬁxed parafﬁn embedded tissue using the Bond automated
immunostainer (Leica Microsystems, Bannockburn, IL). Parafﬁn was
removed with xylene, and the sections were rehydrated in a series of
alcohol washes. Heat-induced epitope retrieval was performed using
citrate (pH 6.0) at 100 °C for 25 min. Orthopoxvirus antigen was
identiﬁed immunohistochemically using a biotinylated rabbit anti-
vaccinia virus polyclonal antibody (1:2000;Catalog#YVS8101,Accurate
Chemical, Westbury, NY) incubated for 15 min at room temperature.
Primary antibody was localized with horseradish peroxidase and
diaminobenzidine substrate. In negative controls, buffer was used in
place of the primary antibody. Sections were counterstained with
hematoxylin and examined by light microscopy by two veterinary
pathologists (AJJ, SY).Acknowledgments
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